Formycon AG (XETR:FYB) Share Price

Company Profile

Business description
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.
Contact
Fraunhoferstrasse 15
Martinsried
PlaneggBY82152
DEU
T: +49 89864667100
https://www.formycon.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
245

Recommended

Investors will get to see if the new strategy and capital management framework are working.

Brian Han | 27 January 2026

These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 27 January 2026

Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.

Sarah Hansen | 26 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,250.60	50.70	-0.55%
CAC 40	8,059.79	93.03	-1.14%
DAX 40	24,803.68	90.76	-0.36%
Dow JONES (US)	49,003.41	408.99	-0.83%
FTSE 100	10,159.40	48.40	-0.47%
HKSE	27,826.91	699.96	2.58%
NASDAQ	23,817.10	215.74	0.91%
Nikkei 225	53,358.71	25.17	0.05%
NZX 50 Index	13,412.87	98.01	-0.73%
S&P 500	6,978.60	28.37	0.41%
S&P/ASX 200	8,933.90	40.40	-0.45%
SSE Composite Index	4,151.24	11.33	0.27%